135 results about "High doses" patented technology

The invention discloses an ultra-high dose rate radiotherapy plan optimization system based on compensator modulation, and relates to the technical field of radiotherapy. A data acquisition module is used for acquiring medical image data of a patient and receiving a clinical target; the clinical target comprises a target region prescription dose, an organ-endangering limit and a minimum dose rate threshold value required for triggering and maintaining a FLASH effect; and the FLASH biological effect evaluation module is used for calculating FLASH biological effective dose distribution corresponding to the physical dose distribution through an embedded biological effect model based on the input physical dose distribution and dose rate distribution. According to the method, the physical dose is converted into the accurate FLASH biological effective dose through the improved linear quadratic model embedded with the FLASH correction factor, the target tumor killing effect is guaranteed, normal tissue protection is enhanced with the help of the tissue differentiation correction factor, the industrial pain point that the physical dose reaches the standard but the biological effect does not reach the expectation is effectively solved, and the application prospect is wide. And the treatment plan better meets the clinical curative effect and safety core requirements.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue involves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, provided are methods which utilize the highest energy layer and a universal range shifter (URS) to facilitate rapid spot arc therapy (RAPIDSPARC™).

The invention discloses an accurate X-ray radiation dose measurement system based on artificial intelligence, which comprises the following steps: acquiring CT image data of a patient and pulse irradiation parameters of radiotherapy equipment through terminal equipment, and calculating a patient specific anatomical structure dynamic influence factor set, a pulse waveform time domain characteristic factor and a tissue interface scattering correction factor; all the parameters are substituted into a dose measurement formula to obtain an accurate X-ray radiation dose value; through a deep fusion image recognition technology (such as a high-resolution anatomical structure, tissue density gradient and heterogeneous region distribution provided by CT / MRI), a secondary particle scattering effect of a junction region of a tumor and a normal tissue can be accurately represented; and dynamic anatomical information (such as respiratory movement and organ displacement) in the image is combined to correct the time characteristic (such as dynamic change under an instantaneous high dose rate) of the pulse radiation field in real time, so that the dose calculation accuracy of a fast algorithm in a complex scene is remarkably improved.

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

A method, system, and device for ultra-low-dose imaging of oral cone-beam computed tomography (CBCT) are provided. The method encompasses high-dose oral CBCT image data acquisition, data segmentation processing, three-dimensional (3D) reconstruction processing, model training, image data input, image enhancement, and image data output. Specifically, the process involves performing 3D reconstruction on 2D projection data of oral CBCT acquired in ultra-low-dose mode to obtain ultra-low-dose oral CBCT 3D reconstructed image data. This ultra-low-dose oral CBCT 3D reconstructed image data is then input into the oral CBCT ultra-low-dose imaging enhancement network model, from which high-quality oral CBCT image data is output for subsequent clinical diagnosis and treatment processes. This method significantly reduces the radiation dose of imaging while ensuring imaging quality, accelerates imaging speed, and enhances the safety of oral CBCT imaging, holding broad clinical application prospects.

This invention provides a modified BoNT / A for treating facial wrinkles, wherein the modified BoNT / A is administered via intramuscular injection at multiple sites on an individual's face, wherein the modified BoNT / A is administered at a unit dose of greater than 1754 pg or greater than 8000 pg per site, wherein the multiple sites are selected from: up to two sites on the corrugator supercilii muscle and one site on the depressor supercilii muscle for treating glabellar lines; up to five sites on the frontalis muscle for treating forehead wrinkles; and up to three sites on the orbicularis oculi muscle for treating lateral canthal wrinkles, wherein the total dose of modified BoNT / A administered during treatment is up to 264,000 pg (and optionally greater than 88,000 pg), and wherein the modified BoNT / A comprises a BoNT / A light chain and a translocation domain (H N The structure domain), and the BoNT / B receptor binding domain (H C (structural domain).

This invention provides a drug-coated balloon catheter, its preparation method, and its application, relating to the field of medical device technology. The drug-coated balloon catheter includes a balloon catheter and a drug coating disposed on the surface of the balloon catheter; the drug coating includes an active drug and an excipient; the active drug is a flavonoid. The drug-coated balloon catheter utilizes flavonoids, which combine the advantages of low toxicity and high water solubility. While reducing the toxic side effects of the drug coating, it achieves rapid release and efficient absorption of the drug. Furthermore, through a dual mechanism of anti-proliferation and anti-inflammation, it effectively solves the problems of potential toxic side effects, limited transport efficiency, and limited functionality that may exist in existing products at high dose densities.

The application discloses an X-ray scanning imaging method based on an X-ray flat panel array, relates to the technical field of scanning imaging, and breaks through the traditional dose constraint by simulating high dose noise characteristics in a projection domain based on virtual dose enhancement; based on dynamic registration of bone probability weighting, the method eliminates the blurred edge of a vertebral body caused by respiratory displacement without the need of external sensors or patient cooperation; by means of an iterative weight shrinkage mechanism, a weighted total variation model can inhibit soft tissue noise while preserving micron-level features such as bone trabeculae, and over-smoothing distortion is avoided; frame frequency control in a respiratory phase is self-adaptive, compatible with existing flat hardware, and can directly upgrade existing equipment, thereby reducing hospital procurement costs.

The application discloses application of a lipoic acid analogue in preparation of a product for relieving myocardial cell hypertrophy, and the lipoic acid analogue DMAE-LA is N -(2-(dimethylamino)ethyl)-5-(1,2-dithiopentyl-3-yl)valeric amide. DMAE-LA can effectively reduce ISO-induced myocardial hypertrophy of mice, reduce heart weight index and ANP and BNP expression, and significantly improve heart function. A small dose (2-10 μM) of a lysosome-targeting lipoic acid analogue DMAE-LA can effectively improve Ang II-induced myocardial hypertrophy and oxidative stress in H9c2 cells, and the protective effect is better than that of a high dose (200-400 μM) of LA. As a new substitute of traditional LA, DMAE-LA shows great potential for prevention and treatment of cardiovascular diseases.

The invention relates to the technical field of medicine packing materials, in particular to a filling process of a novel aripiprazole double-cavity pre-filling syringe, and a syringe barrel of the novel double-cavity pre-filling syringe is made of COP / COC materials; comprising the following steps of sterilization, middle plug placement, sterile filling, freeze drying, plug pressing and assembling, and a complete double-cavity pre-filled syringe is obtained.The filling process combines high strength and heat conduction uniformity of COP / COC materials, in-situ freeze-drying in the syringe is achieved, the step of powder transfer after freeze-drying of a traditional penicillin bottle is avoided, and the production efficiency is improved. According to the present invention, the sterile risk and the production cost are significantly reduced, the manufacturing process is simplified, the equipment complexity and the product loss are reduced, and the high dose accuracy and the yield are ensured.

The invention discloses a high-drug-loading tumor liquid embolism system and application thereof, and belongs to the technical field of medical instruments. The system comprises an embolism polymer solution and a solvent used for dissolving a drug, the polymer can be dissolved at a high concentration by regulating the molecular weight of the block polymer, the solvent used for dissolving the drug can dissolve the high-concentration drug, and high-concentration drug loading is achieved after the solvent used for dissolving the drug is mixed with the embolism polymer solution. The requirements of some disease treatment on high-dose medicines are met.

The invention discloses blood filtration replacement liquid as well as a preparation method and application thereof. The displacement liquid comprises low molecular weight heparin calcium, prostaglandin E1, prostacyclin, electrolyte with specific concentration, glucose and an interleukin-1 receptor antagonist. The preparation method comprises the following steps: weighing the raw materials according to the proportion, dissolving to a constant volume, removing pyrogen and heat, and carrying out aseptic packaging. During clinical application, replacement liquid and blood are filtered according to the replacement rate of 1: 1-2: 1 according to the condition of a patient, 4-6 hours each time and 2-3 times each week, and related indexes are monitored. Animal tests show that the replacement liquid has good safety under the effective dosage, and has potential influence on part of organs under the high dosage. A stability test shows that the compound can be stably stored under a certain condition. The invention provides the replacement liquid which can achieve anticoagulation and blood vessel protection, maintain electrolyte balance and relieve inflammatory response, is expected to improve the prognosis of hemodialysis patients, and has important clinical significance and wide application prospects.

The invention belongs to the technical field of biological medicines, and particularly relates to a honeysuckle total extract inhalation solution as well as a preparation method and application thereof. According to the invention, the honeysuckle total extract with poor water solubility, phospholipid and chitosan are innovatively and directionally assembled into the chitosan-phospholipid nanoparticles with uniform structure, and the nanoparticles are prepared by adopting a microfluidic technology. The strategy significantly improves the water solubility and stability of the honeysuckle total extract, and successfully prepares an inhalation solution suitable for pulmonary administration based on the nanoparticle dispersion system. The obtained preparation has the characteristics of high physical stability and good bioavailability potential. The honeysuckle total extract inhalation solution provided by the invention can effectively relieve the pathological process of the pyotoxic pneumonia through multiple mechanisms of remarkably inhibiting lung inflammatory response, relieving pulmonary edema, protecting the structural integrity of pulmonary alveoli and the like. Especially, a high-dose group shows a curative effect superior to that of a positive control drug, and a good dose-effect relationship is combined, so that the preparation has remarkable development potential and clinical transformation prospect in treatment of the septic pneumonia.

The invention discloses a soluble microneedle loaded with high-dose microspheres, which comprises a substrate and a needle body, and the needle body is internally loaded with biodegradable microspheres in a compact stacking state. Biodegradable microspheres are coated in a needle body of a microneedle array through a soluble material, so that the soluble microneedle which is loaded with the biodegradable microspheres in a compact stacking state and is high in loading capacity is obtained, and the material selection and the structural design of the soluble microneedle are optimized; the microneedle array with various needle body lengths, geometric configurations and arrangement densities can be prepared according to different clinical requirements, and uniform distribution and dense filling of biodegradable microspheres in the needle body are realized, so that efficient delivery of the microspheres is guaranteed. Meanwhile, the biodegradable microspheres can be delivered to the required subcutaneous depth along with dissolution of the needle body by adjusting the length of the needle body, and a safe, effective and non-invasive technical path is provided for percutaneous delivery of the biodegradable microspheres.

The present invention relates the use of botulinum toxin for the treatment of facial wrinkles, wherein botulinum toxin is administered at high doses (e.g., 50 U to 200 U) using small injection volumes (e.g., 0.05 ml to 0.35 ml). Furthermore, the present invention relates to a method for the treatment of facial wrinkles (e.g., glabellar frown lines) by injecting small volumes of a highly concentrated botulinum toxin solution into a target facial area of a subject.

The invention relates to the field of medical accelerators, and discloses a 4-pi stereotactic radiotherapy linear accelerator and a treatment method.The 4-pi stereotactic radiotherapy linear accelerator comprises a main cantilever, a secondary cantilever and a rack rotating assembly, and the main cantilever can rotate along a base in a circle; the rack rotating assembly is rotatably connected to the main cantilever; the secondary rotating arm can slide up and down along the rack rotating assembly, an accelerator is arranged on the top of the secondary rotating arm, and a multi-element collimator is installed on the accelerator. The method is implemented based on the device. The beneficial effects of the invention are that the main cantilever, the secondary cantilever and the rack rotating assembly are in cooperative linkage, so that the treatment efficiency is close to that of a volume arc intensity modulated (VMAT) technology, and the angle and number of beams can be greatly increased, thereby being capable of giving a higher dose to a target area and reducing the dose of surrounding normal tissues, enabling the beams irradiated on the normal tissues to be less, and improving the treatment efficiency. And the tumor tissue has more beams.

This invention relates to a radiotherapy device and experimental method with switchable high and low dose distributions, belonging to the field of radiotherapy experimental technology. It solves the problem in existing technologies where the radiation dose in low-dose experiments in animal radiotherapy cannot be controlled. The invention includes a shielding platform and a shielding end; the shielding end is rotatably mounted on the shielding platform and has light-transmitting holes arranged in an alternating pattern. In this invention, the radiation beam emitted by the radiation source device directly irradiates the experimental animal, allowing for control of the radiation dose, and the high-dose and low-dose irradiation points on the experimental animal are arranged alternately.

The invention provides a composite growth factor composition capable of promoting proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells, a method and application. The invention provides the composite growth factor composition by simulating a natural secretion mode of a decalcified bone matrix of the mandible of an SD (Sprague Dawley) rat on the seventh day, the composite growth factor composition comprises BMP-2 (400-600 pg / ml), TGF-beta1 (5-7 ng / ml) and IGF-1 (150-250 ng / ml), and the optimal concentrations are 500 pg / ml, 6 ng / ml and 200 ng / ml respectively. The composition is remarkably superior to a single factor and a high-dosage combination in the aspects of promoting BMSCs proliferation, improving the activity of alkaline phosphatase (ALP) and forming mineralized nodules, meanwhile, the use dosage of growth factors is remarkably reduced, and the risk of side effects such as heterotopic ossification is reduced. The composite growth factor composition has good biocompatibility and safety, and is suitable for the fields of bone tissue engineering, bone defect repair and related regenerative medicine.

The invention relates to the technical field of biological medicine, and particularly discloses application of Xinjiang pomegranate rind ellagic acid in caries prevention, in-vivo and in-vitro experiments prove that the ellagic acid can effectively inhibit floating growth and biofilm formation of streptococcus mutans, streptococcus sobrinus and streptococcus sanguis, MICs of the ellagic acid are 4 mmol / L, 2 mmol / L and 1 mmol / L respectively, and MBICs of the ellagic acid are 8 mmol / L, 4 mmol / L and 1 mmol / L respectively; meanwhile, the ellagic acid can obviously inhibit the acid production capacity of the cariogenic bacteria, the generation of water-insoluble exopolysaccharides and the adhesion to hydroxyapatite; in a rat caries model, by locally applying 1-8 mmol / L ellagic acid, the number of streptococcus in the oral cavity can be reduced in a dose-dependent manner, the caries damage degree of smooth surfaces of molar teeth and fossa and fissure can be relieved, the effect of the ellagic acid is equivalent to that of positive control drugs chlorhexidine and sodium fluoride under the high dose (8 mmol / L), and the ellagic acid shows good biological safety. Therefore, ellagic acid can be used for preparing safe and effective anti-caries drugs or oral care products.

The present disclosure provides a rack for radiotherapy equipment and a radiotherapy equipment. The rack for radiotherapy equipment comprises a supporting assembly, a drum configured in a horizontal structure, having an axial first end and a second end, both of which are rotatably arranged on the supporting assembly, and a carrier arranged on the outer wall of the first end and adapted to carry an external pulse transformer so that the pulse transformer rotates synchronously with the drum. The drum is adapted to provide a reliable mounting platform for a super high dose rate radiotherapy equipment, so that the particle rays output by a plurality of beam modules configured on the super high dose rate radiotherapy equipment can be accurately converged in the drum. Both the first end and the second end of the drum are rotatably arranged on the supporting assembly to meet the bearing capacity requirements of the drum and other components arranged thereon, so that the rack for radiotherapy equipment forms a reliable mounting platform. The carrier is used to assemble the pulse transformer on the drum and synchronize with the drum.

A method of applying a desired aroma locally and in high doses as a result of application of high aroma inputs and inputs where aroma loss is not desired, onto surfaces of food products. As all surfaces of particulates are mixed and coated with decor food products, contact with air is stopped fully and aroma loss and oxidization are prevented.

A system for mapping oxygen levels in tumors includes a needle that is sized to deliver high dose rate brachytherapy to tissue into which the needle is inserted, where the needle includes a radio frequency micro-coil sensor positioned within a shaft of the needle and a spin probe mounted to an outer surface of the shaft of the needle. A processor is in communication with the needle and configured to move the radio frequency micro-coil sensor along the shaft of the needle. The processor is also configured to receive, from the radio frequency micro-coil sensor, oxygen level readings at a plurality of tissue locations along the shaft of the needle. The processor is also configured to generate an oxygen level mapping of the tissue based on the oxygen level readings received from the radio frequency micro-coil sensor.

The invention relates to a construction method of an experimental autoimmune prostatitis rat model. The construction method comprises the following steps: S1, preparing a prostate specific antigen mixture; s2, selecting male SD rats as laboratory rats, and dividing the laboratory rats into a normal saline control group, a low-dose model group and a high-dose model group; s3, continuously injecting for 7 days, allowing the normal saline control group to accept injection of 0.2 ml of normal saline every day, allowing the low-dose model group to accept injection of 0.1 ml of prostate specific antigen mixture every day, and allowing the high-dose model group to accept injection of 0.2 ml of prostate specific antigen mixture every day; and S4, continuously feeding all groups of experimental mice to the 28th day, inducing the experimental mice in the low-dose model group and the high-dose model group by the prostate specific antigen mixture to cause experimental autoimmune prostatitis, and obtaining the experimental autoimmune prostatitis rat model. The use of animals can be reduced, the cost is reduced, and the modeling efficiency and stability can be improved.

This invention discloses an intelligent adaptive dose verification calculation method and system. The intelligent adaptive dose verification calculation method includes: obtaining preliminary dose distribution data for a patient based on a deep learning-based dose prediction model; dynamically assigning variance reduction parameters to particles in a Monte Carlo simulation based on the high and low dose distribution information in the preliminary dose distribution data, wherein the variance reduction parameters include simulation weights, with simulation weights assigned to particles predicted to be in high-dose regions being less than those assigned to particles predicted to be in low-dose regions; and using a Monte Carlo dose calculation engine, simulating the planned beam based on the dynamically assigned variance reduction parameters to obtain high-precision verification dose distribution data. This invention's intelligent adaptive dose verification calculation method ensures the physical authenticity of the final verification dose distribution and the credibility of the "gold standard."

The utility model provides a high dose product uniform irradiation device, which relates to the irradiation device technology field, and comprises a support frame, a roller conveyor is arranged between the inner walls of the support frame, the lower end surface of the support frame is provided with a bottom frame, and the two side surfaces of the bottom frame are fixedly provided with installation side plates. According to the utility model, the two clamping plates are arranged on the surfaces of the two sides of a product, so that the product is fixed, at the moment, the product is stretched out and drawn back through the output end of the hydraulic cylinder, and the product can be fixed through the clamping plates, so that the product can be fixed, and the production efficiency is improved. At the moment, a connecting plate can be driven to move upwards, two clamping plates can be driven to move upwards, the two clamping plates are driven to rotate through the output ends of two second servo motors, the product can be driven to rotate, and the irradiator irradiates the product comprehensively and evenly.

Radiotherapy is the most widely used and effective anti-tumor therapy, however it can damage healthy tissues surrounding the tumor. One approach to reducing damage to healthy tissue invoves irradiation at dose rates far exceeding those currently used in clinical contexts reduces radiation-induced toxicities while maintaining an equivalent tumor response. This is known as the FLASH effect. The mechanism responsible for reduced tissue toxicity following FLASH radiotherapy (FLASH-RT) is still undetermined; multiple hypotheses have been suggested by linking the high dose rate to rapid oxygen depletion, immune response, reduction of peroxyl radical lifetime, preservation of normal tissue stem cells, etc. While effective, proton therapy is underutilized, contributing to fewer than 2% of all external beam radiation treatments. To overcome this shortcoming, compact radiotherapy systems are provided that incorporate multi-function components, reducing bot equipment size and expense.

Provided are compositions and methods for treating cancers, in particular those characterized with PSMA expression such as prostate cancer. The compositions include a conditionally-activatable XTENylated Protease-Activated bispecific T Cell Engager targeting PSMA (PSMA-XPAT) that remain inactive until activated by proteases present in tumor microenvironment. The PSMA-XPAT exhibited exceptional safety profiles even at high doses and were efficacious in cancer patients resistant to even multiple lines of prior therapies.

The droplet delivery device includes a high dose confidence mode that monitors a user's inhalation of the composition and activates and deactivates aerosol generation by monitoring the user's inhalation to assist the user in completing a full dose of the composition when the user does not inhale the full dose when using the device.

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.

A starch-based injectable hydrogel system for localized cancer treatment. The pre-formed hydrogel delivers chemotherapeutic drugs (such as doxorubicin) and / or medical radionuclides directly to tumor sites while minimizing systemic exposure. The composition uses dimethyl sulfoxide as a solvent and can be stored in pre-filled syringes for clinical use. Key advantages include >90% drug retention, sustained local delivery, and compatibility with image-guided injection techniques. The system is particularly suitable for pediatric brain tumors and other solid tumors requiring localized high-dose therapy.